Citius Pharmac Dl Stock Price To Earning
| 47N Stock | EUR 3.29 0.00 0.00% |
CITIUS PHARMAC DL fundamentals help investors to digest information that contributes to CITIUS PHARMAC's financial success or failures. It also enables traders to predict the movement of CITIUS Stock. The fundamental analysis module provides a way to measure CITIUS PHARMAC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CITIUS PHARMAC stock.
CITIUS |
CITIUS PHARMAC DL Company Price To Earning Analysis
CITIUS PHARMAC's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
Based on the latest financial disclosure, CITIUS PHARMAC DL has a Price To Earning of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The price to earning for all Germany stocks is 100.0% higher than that of the company.
CITIUS Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CITIUS PHARMAC's direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CITIUS PHARMAC could also be used in its relative valuation, which is a method of valuing CITIUS PHARMAC by comparing valuation metrics of similar companies.CITIUS PHARMAC is currently under evaluation in price to earning category among its peers.
CITIUS Fundamentals
| Return On Equity | -0.28 | |||
| Return On Asset | -0.16 | |||
| Shares Outstanding | 146.21 M | |||
| Shares Owned By Insiders | 8.42 % | |||
| Shares Owned By Institutions | 11.00 % | |||
| EBITDA | (33.31 M) | |||
| Net Income | (23.66 M) | |||
| Cash And Equivalents | 115.66 M | |||
| Cash Per Share | 0.79 X | |||
| Total Debt | 1.06 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 32.48 X | |||
| Book Value Per Share | 0.70 X | |||
| Cash Flow From Operations | (22.02 M) | |||
| Earnings Per Share | (0.19) X | |||
| Target Price | 7.0 | |||
| Number Of Employees | 21 | |||
| Beta | 1.2 | |||
| Market Capitalization | 186.2 M |
About CITIUS PHARMAC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CITIUS PHARMAC DL's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CITIUS PHARMAC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CITIUS PHARMAC DL based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in CITIUS Stock
CITIUS PHARMAC financial ratios help investors to determine whether CITIUS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CITIUS with respect to the benefits of owning CITIUS PHARMAC security.